An interventional study of Mass-based response testing (MRT) in Appendiceal Cancer, Colorectal Adenocarcinoma and Peritoneal Metastases, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 81 Years. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Yale University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Appendiceal Neoplasms with a site in United States — 19 open to participants now, 24 under way, 1 of them phase 3. Appendiceal Neoplasms · United States.
Among the 66 studies in Appendiceal Neoplasms with a site in United States, this one is the 41st largest by planned enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 with no phase, reaches primary completion later than 9 of the 23 other live ones, and was the 63rd registered.
86 studies on the registry are indexed under Appendiceal Neoplasms; 25 are open to participants now.
Browse Appendiceal Neoplasms studies →19 of the 66 studies in Appendiceal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Guam, Puerto Rico
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Appendiceal Neoplasms studies recruiting now, 17 (71%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 81 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 16 · Phase 3 3 · Phase 4 1
First in 1997; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 44 across 63 interventional studies indexed under Appendiceal Neoplasms.
Median enrollment 42 across the 52 interventional studies, 120 across the 10 observational. Of the 40 that completed or were terminated, 12 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 66 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 1 study filed under Appendiceal Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Appendiceal Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07587268City of Hope Medical CenterMolecular Profiling for Risk Stratification in Appendiceal Cancer | 2027-01-01 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT04907643Cedars-Sinai Medical CenterVirtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | 2027-03-31 |
| NCT07124351Cedars-Sinai Medical CenterIntraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) | 2027-08-31 |
| NCT01815359Memorial Sloan Kettering Cancer CenterICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis | 2027-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 66 studies in Appendiceal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
Patients with peritoneal metastases from colorectal and appendix cancer are treated with cytoreductive surgery and HIPEC. However, several patients are considered unresectable due to the inability to remove all the cancer safely. Repeated (Iterative) intra-peritoneal chemotherapy delivered via HIPEC laparoscopically has been shown to have favorable outcomes with a potential increase in sensitivity to immunotherapy . Such procedures often use chemotherapy that is not tailored to the patients cancer.
In this study, patients with unresectable colorectal and appendiceal peritoneal metastases will undergo MRT on tissue biopsies to determine optimal chemotherapy regimen to be delivered intraperitoneally. For patients with unresectable disease, iterative HIPEC (IHIPEC) will be administered starting three weeks after the laparoscopy. (IHIPEC refers to HIPEC followed by systemic chemotherapy repeated 3 times with approximately 6 weeks in between each HIPEC.)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has confirmed peritoneal with primary diagnosis of AJCC 8th Edition Stage IV
Limited or no extraperitoneal metastases (any of the below)
a) Any extraperitoneal metastases must be limited, stable and treatable
Demographics
Male Participants
Female Participants
Informed Consent
Alternative Eligibility
Exclusion Criteria:
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
Prior/Concomitant Therapy
Diagnostic Assessments
Note: Testing for HBV and HCV is only required if mandated by the local health authority.
Other Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with high-grade appendiceal and colorectal peritoneal metastasis will receive MRT to select and deliver personalized HIPEC regimens to participants undergoing IHIPEC
Device: Mass-based response testing (MRT)
Travera has developed a clinical workflow that combines single-cell mass measurements with inline brightfield imaging and machine-learning based image classification to perform mass-based response testing (MRT) directly on live tumor cells collected from patients. MRT enables tumor cells across a wide range tissue sample formats to be dosed with a panel of drugs in vitro, agnostic to malignancy or drug mechanism.
Feasibility of performing MRT to select and deliver personalized HIPEC
Feasibility is defined as the percentage of treatment naïve and pretreated patients who successfully receive drug screening results within one week of tissue sampling from at least one peritoneal biopsy. This means that the test has enough tumor cell viability and purity to come back with specific results indicating sensitivities of HIPEC drugs and does not give an inconclusive result (due to insufficient tissue sample).
Time frame: at end of study, up to 12 months
Concordance of MRT Results
Defined as the percentage of patients who receive identical HIPEC recommendations (reflecting the best response to MRT) in both rounds of testing. Concordance will only be evaluated for the subset of patients who have received two biopsies and Travera screenings.
Time frame: at end of study, up to 12 months
One Year Overall Survival (OS)
Overall survival of patients will be measured from two time points: From the diagnosis of peritoneal metastasis to death from any cause at the end of follow-up (1 year). From the first HIPEC procedure to death from any cause at the end of follow-up (1 year).
Time frame: up to 12 months
Percentage of participants with Perioperative and Postoperative Complications
Percentage of participants that experienced any perioperative or postoperative complications will be graded using the CTCAE version 5. Complications will be noted during hospitalization or within 30 days of each HIPEC procedure, and incidence will be measured separately for patients undergoing IHIPEC.
Time frame: up to 12 months
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) mean score
A tool used to assess the quality of life in cancer patients. It contains 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact) 10. It is scored on a 4-point scale (1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much). The EORTC QLQ-C30 instrument also contains 1 global health status/QoL scale that uses a 7-point scale scoring with anchors (1 = very poor and 7 = excellent).
Time frame: every 3 months post last IHIPEC, up to 12 months
Change in Comprehensive Score for Financial Toxicity (COST)
The COST is a standardized instrument for use as a measure of financial toxicity. The COST questionnaire is a patient-friendly tool that has demonstrated reliability, validity, and internal consistency. It has demonstrated an association with health-related quality of life (HRQOL). It contains 12 brief statements about the financial burden, cost, resources, and concerns related to them. It is scored by the patients on a 5-point scale (0=not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4=very much). A composite score is then calculated, with a lower score indicating financial toxicity.
Time frame: every 3 months post last IHIPEC, up to 12 months
Change in Peritoneal Regression Grading Score (PRGS)
PRGS is a scoring system used to assess tumor regression in biopsies from patients with peritoneal metastasis undergoing therapy. Peritoneal punch biopsies will be collected from all four abdominal quadrants at the start of each IHIPEC procedure. The attending pathologist will evaluate each biopsy and assign a grade, ranging from 1 (indicating a complete response) to 4 (indicating no response). These individual scores will then be averaged to calculate the overall PRGS score. The change in PRGS is defined as the difference in PRGS between the first and last IHIPEC procedure that a patient receives.
Time frame: at first IHIPEC post biopsy to last IHIPEC received, up to 12 months
Change in Peritoneal Cancer Index (PCI) Score
The change in PCI score will only be measured for patients undergoing IHIPEC. The PCI is a scoring system used to quantify the extent of peritoneal carcinomatosis. The abdomen is divided into 13 regions and assigned a score ranging from 0 to 3 based on presence and size of peritoneal tumor implants in each region. This score can range from 0 (no evidence of disease) to 39 (extensive disease). PCI scores will be assessed and recorded by the attending physician following peritoneal cavity exploration before each IHIPEC procedure. The change in PCI score is defined as the difference in PCI between the first and last IHIPEC procedure that a patient receives.
Time frame: during each diagnostic laparoscopy at approximately month 1 and month 6
Complete Cytoreduction Rate
The complete cytoreduction rate will only be measured for patients undergoing IHIPEC. This rate is defined by the percentage of patients who receive a CC0 (indicates no residual tumor visible to the naked eye) or CC1 (indicates minimal residual tumor visible) after completing the IHIPEC protocol. This metric assesses the ability of MRT-selected personalized IHIPEC to downstage PM tumor burden and improve the rate of resection.
Time frame: during each IHIPEC cycle, up to 12 months
Mean MRT Turnaround Time
The mean time in days that it takes for MRT personalized drug readouts to come back to the medical team will be recorded: from the time the biopsy is shipped to Travera to the time the personalized drug readouts are made accessible to the medical team.
Time frame: up to 12 months
MRT Success Rate
The percentage of MRT results that come back with specific personalized drug readouts will be recorded. This excludes MRT results that were inconclusive or had an inadequate cancer cell sample or insufficient tumor cell purity to conduct MRT.
Time frame: up to 12 months
MRT Tumor Cell Viability
The percentage of MRT results that come back as inconclusive due to inadequate tumor cell viability will be recorded. Cell viability can be defined as the percentage of tumor cells that have sufficient metabolic activity to undergo accurate MRT testing as to not receive an inconclusive result.
Time frame: up to 12 months
MRT Tumor Cell Purity:
The percentage of MRT results that come back as inconclusive due to inadequate tumor cell purity will be recorded. Tumor cell purity can be defined as the percentage of biopsies submitted for MRT with a sufficient proportion of malignant cancer cells in the tumor mass as to not receive an inconclusive result.
Time frame: up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.